EIM
ATRA icon

Essex Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

Essex Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,036
Closed -$429K – 362
2017
Q3 		$429K Buy
+1,036
New +$390K 0.06% 277

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Essex Investment Management's ATRA Position: Q4 2017 in Review

Essex Investment Management sold out of Atara Biotherapeutics (ATRA) in Q4 2017, closing a stake of 1,036 shares — an estimated $429K sold.

Essex Investment Management first reported a position in ATRA in Q3 2017 and held it in 1 quarter. The position peaked at $429K in Q3 2017. 86 funds tracked by Wall St. Rank hold ATRA as of Q4 2017.

  • Essex Investment Management reported no remaining Atara Biotherapeutics position as of Q4 2017 after selling out during the quarter.
  • Essex Investment Management sold 1,036 Atara Biotherapeutics shares in Q4 2017, an estimated $429K.
  • Essex Investment Management first reported a position in Atara Biotherapeutics in Q3 2017 and held it in 1 quarter.
  • Essex Investment Management's Atara Biotherapeutics position peaked at $429K in Q3 2017.
  • 86 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2017.

Based on Essex Investment Management's 13F filing for Q4 2017, filed 5 Feb 2018.